NVDA
NVIDIA
-- 114.060 TSLA
Tesla
-- 284.650 TSM
Taiwan Semiconductor
-- 172.970 PLTR
Palantir
-- 83.420 INTC
Intel
-- 22.740 
Update
$Olema Pharmaceuticals (OLMA.US)$ Reuters· 1 min ago
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
104079172 : The analyst presentation today of the same data that will be presented at the symposium was extremely good. Good chance the stock price will go up well in the next few days
104079172 : I am surprised that the share price is currently not moving up much to be honest
Trytosaveabit OP 104079172 : Just no volume!
104079172 : Yes indeed. I suspect that most retail investors have their attention elsewhere. And the institutions are in it for the long haul hence the volume is really bad. This company will do well in 12 months. High chance that Novartis might acquire it given that it doesn't currently have a similar promising drug in its own pipeline (it's own type has no news for a long time and Olema seems to be clever enough to partner with Novartis to do a ribo combo with Palazestrant in its ongoing phase trials)